Metropolitan Life Insurance CO Affimed N.V. Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jun 14, 2023	BUY	$1.1 - $2.45 $9,500 - $21,160	8,637 New	8,637 $10.7 Million
Q3 2022 Jun 14, 2023	BUY	$1.96 - $3.32 $16,928 - $28,674	8,637 New	8,637 $17.8 Million
Q2 2022 Jun 20, 2023	BUY	$2.27 - $4.86 $8,927 - $19,114	3,933 New	3,933 $10.9 Million
Q1 2022 Jun 20, 2023	BUY	$3.69 - $5.65 $28,870 - $44,205	7,824 New	7,824 $34.2 Million
Q4 2021 Jun 21, 2023	BUY	$5.37 - $7.07 $168,285 - $221,559	31,338 New	31,338 $173 Million
Q3 2021 Jun 21, 2023	BUY	$5.54 - $7.51 $162,876 - $220,794	29,400 New	29,400 $182 Million
Q1 2021 Jun 26, 2023	BUY	$5.12 - $8.48 $158,228 - $262,065	30,904 New	30,904 $244 Million
Q4 2020 Jun 22, 2023	BUY	$3.16 - $7.03 $75,776 - $168,579	23,980 New	23,980 $140 Million
Q3 2020 Jun 26, 2023	BUY	$3.26 - $4.73 $75,661 - $109,778	23,209 New	23,209 $78.7 Million
Q2 2020 Jun 26, 2023	BUY	$1.58 - $4.63 $39,141 - $114,698	24,773 New	24,773 $114 Million
Q3 2019 Jul 12, 2023	BUY	$2.67 - $3.65 $63,364 - $86,621	23,732 New	23,732 $69.8 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.